Cell therapy has transformed cancer treatment, yet the hurdles of manufacturing patient-derived cell therapies remain a formidable challenge for the industry. Quality and scalability problems lead to high therapeutic costs and limit access to those life-saving treatments.
By harnessing the power of cutting-edge semiconductor technologies, including silicon photonics seamlessly integrated into microfluidic cartridges, Sarcura is orchestrating a transformative shift.
Central to Sarcura's mission is the creation of fully automated manufacturing systems endowed with real-time process and product control. This pioneering platform promises to usher in a new era of cost-effective and secure cell therapies, democratizing access to these critical treatments.
We aim for a 100x production boost and 10x cost reduction, driving the industrialization of cell therapy manufacturing.
Delve deeper at www.sarcura.com, where the future of cancer treatment is being reshaped.
Company Details
- Employees
- 20
- Founded
- -
- Address
- Plöcking 2, Ist Park,austria
- Industry
- Biotechnology
- Website
- http://www.sarcura.com
- HQ
- Klosterneuburg
Sarcura Questions
Sarcura's website is http://www.sarcura.com
Sarcura's LinkedIn profile is https://at.linkedin.com/company/sarcura
Sarcura has
20 employees.
View email and phone details for 20
employees at Sarcura.
Sarcura's industry is
Biotechnology
Sarcura's top competitors are
Ribbon Bio,
Truestream,
Oncoone,
A:head Bio Ag,
Heartbeat.bio Ag,
Quantro Therapeutics Gmbh,
Lexogen,
Proxygen,
Myllia Biotechnology,
Valanx Biotech.
Sarcura's categories are Biotechnology
Sarcura's founding year is 2019
